Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer
PURPOSE: This study proposes optimal tracer-specific threshold-based window levels for PSMA PET-based intraprostatic gross tumour volume (GTV) contouring to reduce interobserver delineation variability.
METHODS: Nine 68Ga-PSMA-11 and nine 18F-PSMA-1007 PET scans including GTV delineations of four expert teams (GTVmanual) and a majority-voted GTV (GTVmajority) were assessed with respect to a registered histopathological GTV (GTVhisto) as the gold standard reference. The standard uptake values (SUVs) per voxel were converted to a percentage (SUV%) relative to the SUVmax. The statistically optimised SUV% threshold (SOST) was defined as those that maximises accuracy for threshold-based contouring. A leave-one-out cross-validation receiver operating characteristic (ROC) curve analysis was performed to determine the SOST for each tracer. The SOST analysis was performed twice, first using the GTVhisto contour as training structure (GTVSOST-H) and second using the GTVmajority contour as training structure (GTVSOST-MA) to correct for any limited misregistration. The accuracy of both GTVSOST-H and GTVSOST-MA was calculated relative to GTVhisto in the 'leave-one-out' patient of each fold and compared with the accuracy of GTVmanual.
RESULTS: ROC curve analysis for 68Ga-PSMA-11 PET revealed a median threshold of 25 SUV% (range, 22-27 SUV%) and 41 SUV% (40-43 SUV%) for GTVSOST-H and GTVSOST-MA, respectively. For 18F-PSMA-1007 PET, a median threshold of 42 SUV% (39-45 SUV%) for GTVSOST-H and 44 SUV% (42-45 SUV%) for GTVSOST-MA was found. A significant pairwise difference was observed when comparing the accuracy of the GTVSOST-H contours with the median accuracy of the GTVmanual contours (median, - 2.5%; IQR, - 26.5-0.2%; p = 0.020), whereas no significant pairwise difference was found for the GTVSOST-MA contours (median, - 0.3%; IQR, - 4.4-0.6%; p = 0.199).
CONCLUSIONS: Threshold-based contouring using GTVmajority-trained SOSTs achieves an accuracy comparable with manual contours in delineating GTVhisto. The median SOSTs of 41 SUV% for 68Ga-PSMA-11 PET and 44 SUV% for 18F-PSMA-1007 PET form a base for tracer-specific window levelling.
TRIAL REGISTRATION: Clinicaltrials.gov ; NCT03327675; 31-10-2017.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
---|---|
Enthalten in: |
European journal of nuclear medicine and molecular imaging - 48(2021), 4 vom: 06. Apr., Seite 1211-1218 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Draulans, Cédric [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 28.05.2021 Date Revised 04.12.2021 published: Print-Electronic ClinicalTrials.gov: NCT03327675 Citation Status MEDLINE |
---|
doi: |
10.1007/s00259-020-05059-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM315952733 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM315952733 | ||
003 | DE-627 | ||
005 | 20231225160028.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00259-020-05059-4 |2 doi | |
028 | 5 | 2 | |a pubmed24n1053.xml |
035 | |a (DE-627)NLM315952733 | ||
035 | |a (NLM)33025093 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Draulans, Cédric |e verfasserin |4 aut | |
245 | 1 | 0 | |a Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.05.2021 | ||
500 | |a Date Revised 04.12.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a ClinicalTrials.gov: NCT03327675 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a PURPOSE: This study proposes optimal tracer-specific threshold-based window levels for PSMA PET-based intraprostatic gross tumour volume (GTV) contouring to reduce interobserver delineation variability | ||
520 | |a METHODS: Nine 68Ga-PSMA-11 and nine 18F-PSMA-1007 PET scans including GTV delineations of four expert teams (GTVmanual) and a majority-voted GTV (GTVmajority) were assessed with respect to a registered histopathological GTV (GTVhisto) as the gold standard reference. The standard uptake values (SUVs) per voxel were converted to a percentage (SUV%) relative to the SUVmax. The statistically optimised SUV% threshold (SOST) was defined as those that maximises accuracy for threshold-based contouring. A leave-one-out cross-validation receiver operating characteristic (ROC) curve analysis was performed to determine the SOST for each tracer. The SOST analysis was performed twice, first using the GTVhisto contour as training structure (GTVSOST-H) and second using the GTVmajority contour as training structure (GTVSOST-MA) to correct for any limited misregistration. The accuracy of both GTVSOST-H and GTVSOST-MA was calculated relative to GTVhisto in the 'leave-one-out' patient of each fold and compared with the accuracy of GTVmanual | ||
520 | |a RESULTS: ROC curve analysis for 68Ga-PSMA-11 PET revealed a median threshold of 25 SUV% (range, 22-27 SUV%) and 41 SUV% (40-43 SUV%) for GTVSOST-H and GTVSOST-MA, respectively. For 18F-PSMA-1007 PET, a median threshold of 42 SUV% (39-45 SUV%) for GTVSOST-H and 44 SUV% (42-45 SUV%) for GTVSOST-MA was found. A significant pairwise difference was observed when comparing the accuracy of the GTVSOST-H contours with the median accuracy of the GTVmanual contours (median, - 2.5%; IQR, - 26.5-0.2%; p = 0.020), whereas no significant pairwise difference was found for the GTVSOST-MA contours (median, - 0.3%; IQR, - 4.4-0.6%; p = 0.199) | ||
520 | |a CONCLUSIONS: Threshold-based contouring using GTVmajority-trained SOSTs achieves an accuracy comparable with manual contours in delineating GTVhisto. The median SOSTs of 41 SUV% for 68Ga-PSMA-11 PET and 44 SUV% for 18F-PSMA-1007 PET form a base for tracer-specific window levelling | ||
520 | |a TRIAL REGISTRATION: Clinicaltrials.gov ; NCT03327675; 31-10-2017 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Delineation | |
650 | 4 | |a Focal boost | |
650 | 4 | |a PSMA PET | |
650 | 4 | |a Prostatic neoplasms | |
650 | 4 | |a Radiotherapy | |
650 | 7 | |a Gallium Isotopes |2 NLM | |
650 | 7 | |a Gallium Radioisotopes |2 NLM | |
650 | 7 | |a Oligopeptides |2 NLM | |
650 | 7 | |a gallium 68 PSMA-11 |2 NLM | |
650 | 7 | |a Edetic Acid |2 NLM | |
650 | 7 | |a 9G34HU7RV0 |2 NLM | |
700 | 1 | |a De Roover, Robin |e verfasserin |4 aut | |
700 | 1 | |a van der Heide, Uulke A |e verfasserin |4 aut | |
700 | 1 | |a Kerkmeijer, Linda |e verfasserin |4 aut | |
700 | 1 | |a Smeenk, Robert J |e verfasserin |4 aut | |
700 | 1 | |a Pos, Floris |e verfasserin |4 aut | |
700 | 1 | |a Vogel, Wouter V |e verfasserin |4 aut | |
700 | 1 | |a Nagarajah, James |e verfasserin |4 aut | |
700 | 1 | |a Janssen, Marcel |e verfasserin |4 aut | |
700 | 1 | |a Isebaert, Sofie |e verfasserin |4 aut | |
700 | 1 | |a Maes, Frederik |e verfasserin |4 aut | |
700 | 1 | |a Mai, Cindy |e verfasserin |4 aut | |
700 | 1 | |a Oyen, Raymond |e verfasserin |4 aut | |
700 | 1 | |a Joniau, Steven |e verfasserin |4 aut | |
700 | 1 | |a Kunze-Busch, Martina |e verfasserin |4 aut | |
700 | 1 | |a Goffin, Karolien |e verfasserin |4 aut | |
700 | 1 | |a Haustermans, Karin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European journal of nuclear medicine and molecular imaging |d 2002 |g 48(2021), 4 vom: 06. Apr., Seite 1211-1218 |w (DE-627)NLM116957360 |x 1619-7089 |7 nnns |
773 | 1 | 8 | |g volume:48 |g year:2021 |g number:4 |g day:06 |g month:04 |g pages:1211-1218 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00259-020-05059-4 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 48 |j 2021 |e 4 |b 06 |c 04 |h 1211-1218 |